Named on 2 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2022-05-03 to 2024-03-14
ROUNDS
2
joined, none as lead
ROUNDS JOINED · USD
$203.2M
across 2 rounds
CO-INVESTORS
13
named beside it
Named on 2 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2022-05-03 to 2024-03-14
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $139.8M | 2024-03-14 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $63.3M | 2022-05-03 | [ PART ] |